Nautilus Biotechnology Past Earnings Performance
Past criteria checks 0/6
Nautilus Biotechnology's earnings have been declining at an average annual rate of -26.6%, while the Life Sciences industry saw earnings growing at 11.7% annually.
Key information
-26.6%
Earnings growth rate
19.6%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | n/a |
| Return on equity | -31.4% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate
Jul 27
We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth
Feb 16Companies Like Nautilus Biotechnology (NASDAQ:NAUT) Are In A Position To Invest In Growth
Oct 22We're Not Very Worried About Nautilus Biotechnology's (NASDAQ:NAUT) Cash Burn Rate
May 25We Think Nautilus Biotechnology (NASDAQ:NAUT) Can Afford To Drive Business Growth
Feb 17Nautilus Biotechnology Q2 2022 Earnings Preview
Aug 01The Take On Nautilus Biotechnology
Jan 17Nautilus Biotechnology: Recent Selloff Provides A Fantastic Entry Point
Jan 07Nautilus Biotechnology: Tapping The Potential Of The Human Proteome
Aug 30Revenue & Expenses Breakdown
How Nautilus Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -70 | 31 | 50 |
| 30 Jun 24 | 0 | -70 | 32 | 50 |
| 31 Mar 24 | 0 | -67 | 30 | 49 |
| 31 Dec 23 | 0 | -64 | 29 | 47 |
| 30 Sep 23 | 0 | -60 | 28 | 44 |
| 30 Jun 23 | 0 | -58 | 27 | 42 |
| 31 Mar 23 | 0 | -57 | 27 | 39 |
| 31 Dec 22 | 0 | -58 | 26 | 38 |
| 30 Sep 22 | 0 | -61 | 26 | 38 |
| 30 Jun 22 | 0 | -62 | 26 | 37 |
| 31 Mar 22 | 0 | -58 | 24 | 34 |
| 31 Dec 21 | 0 | -50 | 21 | 29 |
| 30 Sep 21 | 0 | -39 | 16 | 23 |
| 30 Jun 21 | 0 | -28 | 10 | 18 |
| 31 Mar 21 | 0 | -21 | 6 | 15 |
| 31 Dec 20 | 0 | -16 | 3 | 12 |
Quality Earnings: NAUT is currently unprofitable.
Growing Profit Margin: NAUT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NAUT is unprofitable, and losses have increased over the past 5 years at a rate of 26.6% per year.
Accelerating Growth: Unable to compare NAUT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NAUT is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.7%).
Return on Equity
High ROE: NAUT has a negative Return on Equity (-31.42%), as it is currently unprofitable.